Primary Biliary Cholangitis (PBC) Market: Current Trends and Future Prospects
According to Next Move Strategy Consulting, the global Primary Biliary Cholangitis (PBC) Market is predicted to reach USD 1385 million by 2030 with a CAGR of 9% from 2024 to 2030. Symptoms of PBC include fatigue, itching, dry eyes and mouth, and jaundice. As the disease progresses, it impairs the liver's ability to filter waste, causing significant health complications. Diagnosing PBC involves blood tests to detect specific antibodies and liver enzymes, and a liver biopsy may be used to assess the extent of liver damage.
Download Free Sample: https://www.nextmsc.com/primary-biliary-cholangitis-pbc/request-sample
The treatment for PBC aims to slow disease progression, alleviate symptoms, and prevent complications such as liver failure. Treatment typically includes medications that improve bile flow and reduce liver inflammation. Lifestyle changes, such as avoiding alcohol and maintaining a healthy weight, are also essential. In some cases, a liver transplant may be necessary for patients with advanced PBC.
Market Drivers: Growing Prevalence and Demand for Treatment
The increasing prevalence of PBC worldwide is significantly driving the growth of the PBC market. According to the National Library of Medicine, 22.27 people out of every 100,000 in Europe were diagnosed with PBC in 2021. This rising number of cases has led to an increased demand for effective treatments. Additionally, the global aging population is contributing to the market's expansion, as older adults are more prone to autoimmune diseases, including PBC. The World Health Organization (WHO) estimates that the number of people aged 65 and older will reach 2.1 billion by 2050, further fueling market growth.
Advancements in diagnostic technologies, including imaging techniques such as magnetic resonance elastography (MRE) and magnetic resonance cholangiopancreatography (MRCP), have enabled earlier and more accurate detection of PBC. These advancements are crucial in preventing further liver damage and facilitating better treatment outcomes, which, in turn, support market expansion.
Challenges in the PBC Market: High Diagnostic Costs
Despite the promising growth of the PBC market, high diagnostic costs present a significant barrier to market expansion. Blood tests, imaging procedures, and liver biopsies required for diagnosing PBC can be expensive, especially in low-resource settings. This financial burden may limit access to early diagnosis and treatment, thus hindering the overall market potential.
Emerging Opportunities: Gene Therapy and Novel Treatments
The introduction of novel therapies, such as gene therapy, is expected to revolutionize the treatment landscape for PBC. Gene therapy aims to correct genetic mutations that contribute to the disease, offering the potential for long-term remission and enhanced immune system function. These innovations are expected to create significant opportunities for growth in the PBC market in the coming years. Additionally, new drug therapies, including the use of obeticholic acid and Ursodeoxycholic Acid (UDCA), are expanding the options available for managing PBC and improving patient outcomes.
Inquire Before Buying: https://www.nextmsc.com/primary-biliary-cholangitis-pbc/inquire-before-buying
Market Segmentation
The PBC market is segmented based on several factors, including route of administration, diagnosis, treatment type, end-user, and region.
-
Route of Administration: The market is divided into oral, parenteral, and other routes of administration. Oral treatments, such as UDCA, are most commonly used, though parenteral treatments and novel therapies are expected to grow in demand.
-
Diagnosis: The market includes imaging tests (MRE, MRCP, ultrasound, fibroscan), blood tests (cholesterol tests, antibody tests), and liver function tests. These diagnostic tools are essential for accurate and early detection of PBC.
-
Treatment Type: Key treatment types include liver transplantation, drug therapies like UDCA and obeticholic acid, and emerging treatments such as gene therapy. Drug therapy is a major treatment segment, with new medications being developed and tested to address the needs of PBC patients.
-
End-User: The end-user segment includes hospitals, specialty clinics, homecare settings, and others. Hospitals and specialty clinics are the primary care providers for PBC patients, but homecare options are becoming more prevalent as treatments become more accessible.
-
Region: Geographically, the PBC market is divided into North America, Europe, Asia-Pacific, and the Rest of the World (RoW). North America holds the largest market share due to high PBC incidence rates and access to advanced healthcare infrastructure. In particular, the U.S. sees high prevalence rates, with the American Liver Foundation reporting 65 out of every 100,000 women diagnosed with PBC in 2021. The U.S. healthcare system's robust expenditure and infrastructure support the ongoing growth of the market.
Regional Analysis: North America and Asia-Pacific
North America dominates the PBC market, driven by rising prevalence and strong demand for treatments. Changes in lifestyle, diet, and environmental factors contribute to the increase in PBC cases. Furthermore, North America benefits from well-developed healthcare systems and advanced diagnostic techniques, making it a crucial hub for PBC market growth.
In contrast, the Asia-Pacific region is expected to witness steady growth, mainly due to an aging population in countries like Japan, China, and Thailand. The geriatric population in Japan, in particular, is notably high, with over 30% of its population aged 65 and older, according to the World Bank. This demographic shift is expected to drive the demand for PBC treatments in the region.
Key Players in the PBC Market
Several major players are active in the PBC market, including Ipsen, Gannex Pharma, Intercept Pharma, Pfizer, Genfit, Teva Pharmaceutical Industries, Novartis, Johnson & Johnson, and Bayer. These companies are adopting strategies such as product launches, partnerships, and clinical trials to maintain their market position. Notable developments include Gannex Pharma's phase 2 trial for a PBC drug and Ipsen's partnership with GENEFIT to develop and commercialize the Elafibranor medication for PBC.
Conclusion
The PBC market is poised for substantial growth due to increasing disease prevalence, advancements in diagnostics and treatment options, and a growing aging population. While challenges such as high diagnostic costs remain, innovations like gene therapy offer promising solutions. As the demand for effective PBC treatments continues to rise, key players in the industry are poised to drive further market expansion through strategic partnerships and novel therapies.
For more information, please contact:
Next Move Strategy Consulting
E-Mail: info@nextmsc.com
Direct: +1-217-650-7991
Website: www.nextmsc.com
Follow Us: LinkedIn | Twitter | Facebook | Instagram | YouTube
About Next Move Strategy Consulting:
Next Move Strategy Consulting is a premier market research and management consulting firm that has been committed to provide strategically analysed well documented latest research reports to its clients. The research industry is flooded with many firms to choose from, what makes Next Move different from the rest is its top-quality research and the obsession of turning data into knowledge by dissecting every bit of it and providing fact-based research recommendation that is supported by information collected from over 500 million websites, paid databases, industry journals and one on one consultations with industry experts across a diverse range of industry sectors. The high-quality customized research reports with actionable insights and excellent end-to-end customer service help our clients to take critical business decisions that enables them to move beyond time and have competitive edge in the industry.
We have been servicing over 1000 customers globally that includes 90% of the Fortune 500 companies over a decade. Our analysts are constantly tracking various high growth markets and identifying hidden opportunities in each sector or the industry. We provide one of the industry’s best quality syndicates as well as custom research reports across 10 different industry verticals. We are committed to deliver high quality research solutions in accordance to your business needs. Our industry standard delivery solutions that range from the pre consultation to after-sales services, provide an excellent client experience and ensure right strategic decision making for businesses.